Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer - Results of NRG Oncology/Gynecologic Oncology Group study GOG-0213: a multicentre, open-label, randomised, phase 3 trial
ESGO eAcademy. Coleman R. 01/29/20; 288002 Topic: Management
Dr. Robert L Coleman
Dr. Robert L Coleman
Login now to access Regular content available to all registered users.
Click here to create a free account.

Access to Premium content is currently a membership benefit.

Click here to join ESGO or renew your membership.

You may also access ESGO content "anytime, anywhere" with the FREE ESGO eAcademy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies